Developer docs
API playgroundTry for free, no card

Search company profiles

Berlin Heart Inc.

Full company profile

uuid00snron

Namestring
Berlin Heart Inc.
Legal namestring
Berlin Heart GmbH
Websiteurl
berlinheart.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Berlin Heart Inc. is the wholly owned North American subsidiary (founded October 2005, headquartered in The Woodlands, Texas) of Berlin Heart GmbH, a German medical device company that develops, manufactures, and markets ventricular assist devices (VADs) for mechanical circulatory support. The company's core technology centers on paracorporeal, pulsatile membrane pumps connected to the heart via implantable silicone cannulae, enabling left, right, or biventricular support. Berlin Heart's lead product is the EXCOR Pediatric — the only VAD system specifically designed for infants, children, and adolescents with life-threatening heart failure refractory to optimal medical therapy — which received FDA HDE approval in December 2011 and FDA PMA approval in June 2017. The portfolio has expanded to include the EXCOR Adult VAD (CE-marked internationally but not FDA approved), the EXCOR Venous Cannula (CE approved March 2021 for failing Fontan / single-ventricle patients), and the investigational EXCOR Active device under IDE# G200252.

Berlin Heart positions itself as the only company worldwide able to provide mechanical circulatory support to patients of every age and size, supported by an extensive range of blood pump sizes and cannula configurations. The company monetizes through direct hardware sales of EXCOR systems to specialized cardiac centers and hospitals, complemented by recurring cannula and pump replacement revenue, with quote-based institutional pricing that is not publicly disclosed. Distribution is handled by the wholly owned North American subsidiary (covering the U.S., Canada, and Mexico) and the German parent (covering Europe and international markets), reaching 170+ specialized centers worldwide. Since first clinical use in 1990, EXCOR Pediatric has supported more than 2,000 young patients, with published IDE study outcomes including 96% 30-day survival (vs. 67–75% for ECMO comparators) and 73% successful bridge-to-transplant or weaning rates.

The business model combines an enterprise field-sales GTM motion with deep clinical support: a Clinical Affairs Team advises implanting centers on patient selection, device choice, implantation, and postoperative management, supplemented by annual training symposia, onsite education, and a 24/7 medical and technical hotline. Strategic co-development partnerships with three leading heart centers — German Heart Institute Berlin, Hospital for Sick Kids Toronto, and Texas Children's Hospital Houston — together with support for the ACTION learning network anchor Berlin Heart's clinical ecosystem. The company is privately held under family-investment ownership with 11–50 employees in the U.S. subsidiary and no disclosed external funding rounds.

Short descriptiontext

Berlin Heart Inc. develops and markets the EXCOR family of paracorporeal pulsatile ventricular assist devices, providing mechanical circulatory support as bridge-to-transplant for pediatric and adult patients with severe heart failure at 170+ specialized cardiac centers worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersThe Woodlands, United States
HQ citystring
The Woodlands
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mechanical circulatory support, ventricular assist devices, pediatric cardiac devices, heart failure therapy, medical device manufacturing
Industry3 codes
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAH
Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Mechanical Circulatory Support Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Berlin Heart develops, produces and markets innovative devices for mechanically supporting the heart. The company generates revenue through the sale of their EXCOR mechanical circulatory support systems to hospitals and healthcare institutions worldwide.

berlinheart.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components7 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Berlin Heart Inc. develops, manufactures, and supports ventricular assist device (VAD) systems under the EXCOR product line, including paracorporeal pulsatile membrane pumps and implantable silicone cannulae that provide left, right, or biventricular support as a bridge to transplant or recovery. The portfolio spans pediatric and adult patients and is sold to specialized cardiac care hospitals and healthcare institutions, primarily in North America.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 96% 30-day survival rate in IDE study cohort 1 (vs 75% for ECMO group)
+4 more records
Product overview1 text field

Berlin Heart develops, manufactures, and markets innovative ventricular assist devices (VADs) for mechanical circulatory support. The company offers two core products: the EXCOR Pediatric and EXCOR Adult mechanical circulatory support systems. The EXCOR system uses paracorporeal, pulsatile membrane pumps with implantable silicone cannulae to provide left ventricular, right ventricular, or biventricular support for patients of all ages and sizes. As of 2021, the company expanded its portfolio with the CE-approved EXCOR Venous Cannula for Fontan patients. The EXCOR Pediatric is FDA-approved (PMA, 2017) for bridge-to-transplant use in pediatric patients, while EXCOR Adult and several other configurations are not yet FDA approved.

Product and service4 records
1EXCOR Pediatric
2EXCOR Adult
3EXCOR Venous Cannula
4EXCOR Active
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership with one of the world's leading heart centers. Part of Berlin Heart's strategic international expansion focused on innovative products and partnerships.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership with one of the world's leading heart centers. Part of Berlin Heart's strategic international expansion focused on innovative products and partnerships.

3Texas Children's Hospital (Houston, Texas)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership with one of the world's leading heart centers. Berlin Heart Inc. is located in Texas and maintains close partnership with this major pediatric cardiac center.

berlinheart.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ACTION brings together clinicians, researchers, parents, and patients from across medical institutions to improve outcomes for children with heart failure. Berlin Heart supports this learning network and collaborative practices methodology for quality improvement.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medtronic acquired HeartWare International and its HVAD System, a miniaturized implantable centrifugal VAD for advanced heart failure. Broad incumbent with significant VAD clinical data and global commercial reach; overlaps with Berlin Heart in the VAD category though concentrated in adult continuous-flow devices.

TypeDirect peer
Description

SynCardia manufactures the only FDA-approved total artificial heart (TAH), a pulsatile mechanical circulatory support device used as bridge to transplant. Directly comparable to Berlin Heart as a niche manufacturer of pulsatile mechanical circulatory support devices for severe heart failure.

TypeEmerging player
Description

BiVACOR is developing a total artificial heart using magnetic levitation rotor technology for severe biventricular failure. Emerging player with overlap in mechanical circulatory support category, though targeting total heart replacement rather than ventricular assist.

4Carmat
TypeEmerging player
Description

Carmat develops a bioprosthetic total artificial heart as bridge to transplant for end-stage heart failure. Emerging player in mechanical circulatory support with overlapping use cases though differentiated technology; CE-marked in Europe and pursuing further indications.

TypeEmerging player
Description

CorWave is developing a next-generation LVAD using a wave-membrane pumping mechanism to reduce blood trauma. Emerging player in mechanical circulatory support with overlapping clinical use case for advanced heart failure.

TypeDirect peer
Description

Jarvik Heart develops the Jarvik 2000, a continuous-flow LVAD for destination therapy and bridge to transplant, and has explored pediatric applications. Comparable as a small, focused VAD developer with overlapping bridge-to-transplant clinical use case.

7Terumo (Terumo Cardiovascular)
TypeBroad incumbent
Description

Terumo developed the DuraHeart LVAD and broader mechanical circulatory support portfolio through Terumo Cardiovascular. Broad incumbent in cardiac surgery and mechanical support products with overlapping VAD technology, though not focused on pediatric niche.

8ReliantHeart
TypeDirect peer
Description

ReliantHeart developed the aVAD, a small continuous-flow VAD with remote monitoring capability for advanced heart failure. Direct peer in the VAD space targeting bridge-to-transplant and destination therapy indications.

9Evaheart, Inc.
TypeEmerging player
Description

Evaheart developed a continuous-flow LVAD (EvaHeart2) targeting destination therapy. Emerging VAD competitor with overlap in the bridge-to-transplant and long-term mechanical support category.

10Abbott
TypeBroad incumbent
Description

Abbott markets HeartMate 3, the leading continuous-flow LVAD for adult advanced heart failure, and CentriMag for short-term circulatory support. Broad incumbent in mechanical circulatory support with overlapping technology, larger portfolio, and vastly greater resources, though focused on adult rather than pediatric indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Berlin Heart Inc.

Mechanical Circulatory Support Devicesberlinheart.com

Berlin Heart Inc. develops and markets the EXCOR family of paracorporeal pulsatile ventricular assist devices, providing mechanical circulatory support as bridge-to-transplant for pediatric and adult patients with severe heart failure at 170+ specialized cardiac centers worldwide.

What Berlin Heart Inc. does

Berlin Heart Inc. is the wholly owned North American subsidiary (founded October 2005, headquartered in The Woodlands, Texas) of Berlin Heart GmbH, a German medical device company that develops, manufactures, and markets ventricular assist devices (VADs) for mechanical circulatory support. The company's core technology centers on paracorporeal, pulsatile membrane pumps connected to the heart via implantable silicone cannulae, enabling left, right, or biventricular support. Berlin Heart's lead product is the EXCOR Pediatric — the only VAD system specifically designed for infants, children, and adolescents with life-threatening heart failure refractory to optimal medical therapy — which received FDA HDE approval in December 2011 and FDA PMA approval in June 2017. The portfolio has expanded to include the EXCOR Adult VAD (CE-marked internationally but not FDA approved), the EXCOR Venous Cannula (CE approved March 2021 for failing Fontan / single-ventricle patients), and the investigational EXCOR Active device under IDE# G200252.

Berlin Heart positions itself as the only company worldwide able to provide mechanical circulatory support to patients of every age and size, supported by an extensive range of blood pump sizes and cannula configurations. The company monetizes through direct hardware sales of EXCOR systems to specialized cardiac centers and hospitals, complemented by recurring cannula and pump replacement revenue, with quote-based institutional pricing that is not publicly disclosed. Distribution is handled by the wholly owned North American subsidiary (covering the U.S., Canada, and Mexico) and the German parent (covering Europe and international markets), reaching 170+ specialized centers worldwide. Since first clinical use in 1990, EXCOR Pediatric has supported more than 2,000 young patients, with published IDE study outcomes including 96% 30-day survival (vs. 67–75% for ECMO comparators) and 73% successful bridge-to-transplant or weaning rates.

The business model combines an enterprise field-sales GTM motion with deep clinical support: a Clinical Affairs Team advises implanting centers on patient selection, device choice, implantation, and postoperative management, supplemented by annual training symposia, onsite education, and a 24/7 medical and technical hotline. Strategic co-development partnerships with three leading heart centers — German Heart Institute Berlin, Hospital for Sick Kids Toronto, and Texas Children's Hospital Houston — together with support for the ACTION learning network anchor Berlin Heart's clinical ecosystem. The company is privately held under family-investment ownership with 11–50 employees in the U.S. subsidiary and no disclosed external funding rounds.

Berlin Heart Inc. firmographics

Firmographics
Name
Berlin Heart Inc.
Legal name
Berlin Heart GmbH
Website
https://berlinheart.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Berlin Heart Inc. develops and markets the EXCOR family of paracorporeal pulsatile ventricular assist devices, providing mechanical circulatory support as bridge-to-transplant for pediatric and adult patients with severe heart failure at 170+ specialized cardiac centers worldwide.
Ownership category
akta.pro rank

Berlin Heart Inc. industry classification

Industry
Product category
Mechanical Circulatory Support Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAH
Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Mechanical circulatory support
  • Ventricular assist devices
  • Pediatric cardiac devices
  • Heart failure therapy
  • Medical device manufacturing

Where Berlin Heart Inc. is headquartered

Location

Headquarters

HQ city
The Woodlands
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Berlin Heart Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Medical Device Sales: Berlin Heart develops, produces and markets innovative devices for mechanically supporting the heart. The company generates revenue through the sale of their EXCOR mechanical circulatory support systems to hospitals and healthcare institutions worldwide.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Berlin Heart Inc. product offering

Product offering

Core offering

Berlin Heart Inc. develops, manufactures, and supports ventricular assist device (VAD) systems under the EXCOR product line, including paracorporeal pulsatile membrane pumps and implantable silicone cannulae that provide left, right, or biventricular support as a bridge to transplant or recovery. The portfolio spans pediatric and adult patients and is sold to specialized cardiac care hospitals and healthcare institutions, primarily in North America.

Product overview

Berlin Heart develops, manufactures, and markets innovative ventricular assist devices (VADs) for mechanical circulatory support. The company offers two core products: the EXCOR Pediatric and EXCOR Adult mechanical circulatory support systems. The EXCOR system uses paracorporeal, pulsatile membrane pumps with implantable silicone cannulae to provide left ventricular, right ventricular, or biventricular support for patients of all ages and sizes. As of 2021, the company expanded its portfolio with the CE-approved EXCOR Venous Cannula for Fontan patients. The EXCOR Pediatric is FDA-approved (PMA, 2017) for bridge-to-transplant use in pediatric patients, while EXCOR Adult and several other configurations are not yet FDA approved.

Differentiator

Problem solved

Functional benefit

Products and services

  • EXCOR Pediatric
  • EXCOR Adult
  • EXCOR Venous Cannula
  • EXCOR Active

Quantifiable outcome

  • 96% 30-day survival rate in IDE study cohort 1 (vs 75% for ECMO group)
  • +4 more outcomes

Companies that use Berlin Heart Inc.

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Berlin Heart Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Berlin Heart Inc. partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • German Heart Institute Berlin (DHZB)coreStrategic or Co-development PartnerStrategic partnership with one of the world's leading heart centers. Part of Berlin Heart's strategic international expansion focused on innovative products and partnerships.
  • Hospital for Sick Kids (Toronto, Canada)coreStrategic or Co-development PartnerStrategic partnership with one of the world's leading heart centers. Part of Berlin Heart's strategic international expansion focused on innovative products and partnerships.
  • Texas Children's Hospital (Houston, Texas)coreStrategic or Co-development PartnerStrategic partnership with one of the world's leading heart centers. Berlin Heart Inc. is located in Texas and maintains close partnership with this major pediatric cardiac center.
  • ACTION (Advanced Cardiac Therapies Improving Outcomes Network)coreStrategic or Co-development PartnerACTION brings together clinicians, researchers, parents, and patients from across medical institutions to improve outcomes for children with heart failure. Berlin Heart supports this learning network and collaborative practices methodology for quality improvement.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Berlin Heart Inc. competitors and assessment

Company assessment

Broad incumbents

  • Medtronic: Medtronic acquired HeartWare International and its HVAD System, a miniaturized implantable centrifugal VAD for advanced heart failure. Broad incumbent with significant VAD clinical data and global commercial reach; overlaps with Berlin Heart in the VAD category though concentrated in adult continuous-flow devices.
  • Terumo (Terumo Cardiovascular): Terumo developed the DuraHeart LVAD and broader mechanical circulatory support portfolio through Terumo Cardiovascular. Broad incumbent in cardiac surgery and mechanical support products with overlapping VAD technology, though not focused on pediatric niche.
  • Abbott: Abbott markets HeartMate 3, the leading continuous-flow LVAD for adult advanced heart failure, and CentriMag for short-term circulatory support. Broad incumbent in mechanical circulatory support with overlapping technology, larger portfolio, and vastly greater resources, though focused on adult rather than pediatric indications.

Direct peers

  • SynCardia Systems: SynCardia manufactures the only FDA-approved total artificial heart (TAH), a pulsatile mechanical circulatory support device used as bridge to transplant. Directly comparable to Berlin Heart as a niche manufacturer of pulsatile mechanical circulatory support devices for severe heart failure.
  • Jarvik Heart: Jarvik Heart develops the Jarvik 2000, a continuous-flow LVAD for destination therapy and bridge to transplant, and has explored pediatric applications. Comparable as a small, focused VAD developer with overlapping bridge-to-transplant clinical use case.
  • ReliantHeart: ReliantHeart developed the aVAD, a small continuous-flow VAD with remote monitoring capability for advanced heart failure. Direct peer in the VAD space targeting bridge-to-transplant and destination therapy indications.

Emerging players

  • BiVACOR: BiVACOR is developing a total artificial heart using magnetic levitation rotor technology for severe biventricular failure. Emerging player with overlap in mechanical circulatory support category, though targeting total heart replacement rather than ventricular assist.
  • Carmat: Carmat develops a bioprosthetic total artificial heart as bridge to transplant for end-stage heart failure. Emerging player in mechanical circulatory support with overlapping use cases though differentiated technology; CE-marked in Europe and pursuing further indications.
  • CorWave: CorWave is developing a next-generation LVAD using a wave-membrane pumping mechanism to reduce blood trauma. Emerging player in mechanical circulatory support with overlapping clinical use case for advanced heart failure.
  • Evaheart, Inc. Evaheart developed a continuous-flow LVAD (EvaHeart2) targeting destination therapy. Emerging VAD competitor with overlap in the bridge-to-transplant and long-term mechanical support category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Berlin Heart Inc. social profiles

Digital presence

Berlin Heart Inc. compliance and trust

Trust signal

Compliance3 records

Berlin Heart Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Berlin Heart Inc. leadership team

Management profile

Number of profiles

Profiles6 records

Berlin Heart Inc. subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Berlin Heart Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Berlin Heart Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Berlin Heart Inc.

What does Berlin Heart Inc. do?

Berlin Heart Inc. develops, manufactures, and supports ventricular assist device (VAD) systems under the EXCOR product line, including paracorporeal pulsatile membrane pumps and implantable silicone cannulae that provide left, right, or biventricular support as a bridge to transplant or recovery. The portfolio spans pediatric and adult patients and is sold to specialized cardiac care hospitals and healthcare institutions, primarily in North America.

Is Berlin Heart Inc. a public or private company?

Berlin Heart Inc. is a private company. It is classified as corporate owned and is currently operating.

When was Berlin Heart Inc. founded?

Berlin Heart Inc. was founded in 2005. It employs 11 to 50 people.

Where is Berlin Heart Inc. based?

Berlin Heart Inc. is headquartered in The Woodlands, United States, in the North America region.

How does Berlin Heart Inc. make money?

One revenue line is on record: medical Device Sales.

Who are Berlin Heart Inc.'s main competitors?

Broad incumbents on record are Medtronic, Terumo (Terumo Cardiovascular) and Abbott. Direct peers are SynCardia Systems, Jarvik Heart and ReliantHeart. Emerging players are BiVACOR, Carmat, CorWave and Evaheart, Inc..

Does Berlin Heart Inc. have an API?

No public API is recorded for Berlin Heart Inc..

What industry is Berlin Heart Inc. in?

Berlin Heart Inc.'s product category is Mechanical Circulatory Support Devices. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO), with a secondary code of HLAHAFAH, Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals